Skip to: [Content] [Navigation]

Zargis Medical Receives Top Honors at Medical Design Excellence Awards

Stamford, CT (June 10, 2010): Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announced that its Zargis Cardioscan heart sounds analysis software and the compatible 3M™ Littmann® Electronic Stethoscope Model 3200 jointly received the highest honor—a Gold Award—as part of the 2010 Medical Design Excellence Award competition.

The Medical Design Excellence Award competition recognizes contributions and advances in the design of medical products. Entries were evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions that improve healthcare delivery and change traditional medical attitudes or practices, features that provide enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so that the product meets its clinical objectives.

The novel stethoscope/software system, which was named 2009 Popular Science "Innovation of the Year", also received top-honors in the Electronics and Computers category of the prestigious 2010 Edison Award competition.

The 2010 Medical Design Excellence Award winners were announced and honored at a June 9 ceremony during the Medical Design & Manufacturing (MD&M) East Conference and Exposition in New York.

About Zargis Medical Corp.

Zargis is a global medical device company focused on improving health outcomes and cost-effectiveness through diagnostic support software and innovation. Zargis is majority-owned by Speedus Corp. (Nasdaq: SPDE), and both 3M Company and Siemens Corporate Research, a division of Siemens AG (NYSE: SI), hold equity positions.

For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or phodge@zargis.com, or visit the following Web sites: www.zargis.com and www.speedus.com.

# # #

Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.